For this 37th annual special report, Med Ad News editors rank the world’s top 50 companies that generate revenue from prescription medicines and healthcare products.
While GlaxoSmithKline is anticipating a slower uptake of respiratory syncytial virus vaccine Arexvy, CEO Emma Walmsley said Wednesday the company is pinning much of its growth on the vaccine’s performance.
Bristol Myers Squibb said on Wednesday evening its CEO Giovanni Caforio would step down in November and will be replaced by current Chief Commercialization Officer Chris Boerner, as the drugmaker contends with increasing generic competition for its top-selling drugs.
GSK on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix and unveiled an upbeat forecast for 2023.
Novartis on Wednesday predicted that core operating income would grow in a “mid single digit” percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business.
Eli Lilly and Co. on Tuesday forecast its annual profit and revenue below estimates, as a stronger dollar piled more pressure on the drugmaker struggling with lower insulin prices and generic competition for its cancer drug.
French drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price.
Gilead Sciences Inc. on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped offset lower sales of its COVID-19 antiviral drug and acquisition expenses.
Abbott Laboratories on Wednesday raised its annual earnings forecast for the second time, citing strong demand for medical devices and COVID-19 diagnostic tests.
For Med Ad News’ 36th annual special report, the publication’s editors rank the world’s top 50 companies that generate revenue from prescription medicines and healthcare products.